A recent study indicates that individuals who stop using new slimming jabs like Mounjaro or Wegovy can put back on shed pounds much more quickly than those who stop conventional diet and exercise plans.
Findings released in a major medical journal shows that while obese individuals frequently drop a large proportion of their total mass while on the medication, the mass returns at an estimated rate of 0.8 kg per month once they quit.
"Users buying such medications need to be informed of the danger of fast weight regain when the therapy is stopped," cautioned expert Dr. Susan Jebb.
This pace of regain implies a return to starting weight in about one and a half years.
Comparing Treatments
The analysis, which reviewed dozens of trials involving thousands of patients, compared the results of the injectable medications with other pills.
The team emphasize that people who shed pounds through lifestyle changes alone usually see a slower weight regain—perhaps 100 grams monthly—after stopping.
Understanding the Fast Rebound
Doctors believe the mechanism of the drugs is key to understanding the heightened rebound.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations far above than normal could lead to the system to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement means hunger is no longer kept in check, making excessive eating a significant risk."
A Lifelong Disease?
The NHS advise the jabs for people with obesity-related health risks, accompanied by recommended lifestyle changes.
Many experts contend that, given the high risk of weight regain, the treatment is often ongoing.
This opinion is reinforced by drug manufacturers, who note that the findings "underscore the long-term nature of obesity," similar to managing diseases like diabetes.
User Testimonies
People who have discontinued the jabs explain a intense return of hunger.
"It was like something activating and you become ravenous," said one woman.
This challenge is compounded if individuals have not developed permanent lifestyle or habit changes during therapy.
Widespread Adoption
Survey data suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Use is greater among women compared to men.
- The middle-aged age group shows the greatest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective agents for shedding pounds, they are not a standalone cure and lasting health benefits likely depends on combined behavioural management.
